PGNX - Progenics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
516.96M
Enterprise Value 3
502.05M
Trailing P/E
N/A
Forward P/E 1
-7.91
PEG Ratio (5 yr expected) 1
-0.02
Price/Sales (ttm)
22.38
Price/Book (mrq)
9.04
Enterprise Value/Revenue 3
21.74
Enterprise Value/EBITDA 6
-7.89

Trading Information

Stock Price History

Beta (3Y Monthly) 2.80
52-Week Change 39.67%
S&P500 52-Week Change 313.08%
52 Week High 36.31
52 Week Low 33.42
50-Day Moving Average 35.31
200-Day Moving Average 34.99

Share Statistics

Avg Vol (3 month) 31.29M
Avg Vol (10 day) 31.09M
Shares Outstanding 586.42M
Float 70.41M
% Held by Insiders 16.46%
% Held by Institutions 186.34%
Shares Short (Oct 31, 2019) 46.28M
Short Ratio (Oct 31, 2019) 44.15
Short % of Float (Oct 31, 2019) 410.03%
Short % of Shares Outstanding (Oct 31, 2019) 47.25%
Shares Short (prior month Sep 30, 2019) 410.41M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Sep 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-285.65%

Management Effectiveness

Return on Assets (ttm)-26.40%
Return on Equity (ttm)-84.28%

Income Statement

Revenue (ttm)23.1M
Revenue Per Share (ttm)0.27
Quarterly Revenue Growth (yoy)5.60%
Gross Profit (ttm)15.62M
EBITDA -63.61M
Net Income Avi to Common (ttm)-71.98M
Diluted EPS (ttm)-0.85
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)64.49M
Total Cash Per Share (mrq)0.75
Total Debt (mrq)56.65M
Total Debt/Equity (mrq)101.28
Current Ratio (mrq)3.76
Book Value Per Share (mrq)0.65

Cash Flow Statement

Operating Cash Flow (ttm)-64.78M
Levered Free Cash Flow (ttm)-48.74M